As an alternative approach, a greater understanding of the mechanisms by which oncogenic KRAS drives immune evasion may identify novel immunotherapy combination strategies that could improve outcomes for patients with KRAS-mutant lung cancer. This evidence concerns the gene KRAS and lung carcinoma.